United Therapeutics Corporation (NASDAQ:UTHR) Shares Bought by IFP Advisors Inc

IFP Advisors Inc raised its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 103.4% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,739 shares of the biotechnology company's stock after acquiring an additional 884 shares during the period. IFP Advisors Inc's holdings in United Therapeutics were worth $536,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the stock. Anchor Investment Management LLC increased its position in shares of United Therapeutics by 12.0% during the fourth quarter. Anchor Investment Management LLC now owns 280 shares of the biotechnology company's stock valued at $99,000 after acquiring an additional 30 shares during the last quarter. Hohimer Wealth Management LLC boosted its stake in shares of United Therapeutics by 0.3% in the first quarter. Hohimer Wealth Management LLC now owns 12,651 shares of the biotechnology company's stock valued at $3,900,000 after purchasing an additional 37 shares during the period. Dunhill Financial LLC boosted its stake in shares of United Therapeutics by 100.0% in the fourth quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company's stock valued at $35,000 after purchasing an additional 50 shares during the period. Two Sigma Investments LP boosted its stake in shares of United Therapeutics by 3.0% in the fourth quarter. Two Sigma Investments LP now owns 1,773 shares of the biotechnology company's stock valued at $626,000 after purchasing an additional 52 shares during the period. Finally, Freedom Investment Management Inc. boosted its stake in shares of United Therapeutics by 6.5% in the fourth quarter. Freedom Investment Management Inc. now owns 869 shares of the biotechnology company's stock valued at $307,000 after purchasing an additional 53 shares during the period. 94.08% of the stock is currently owned by institutional investors and hedge funds.

United Therapeutics Trading Down 0.6%

Shares of United Therapeutics stock traded down $1.91 during trading on Friday, reaching $304.50. The company's stock had a trading volume of 310,921 shares, compared to its average volume of 372,488. The company has a 50-day moving average price of $300.01 and a two-hundred day moving average price of $316.20. The firm has a market cap of $13.74 billion, a PE ratio of 12.15, a P/E/G ratio of 6.68 and a beta of 0.53. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 EPS for the quarter, beating analysts' consensus estimates of $6.29 by $0.34. The business had revenue of $794.40 million for the quarter, compared to analysts' expectations of $726.82 million. United Therapeutics had a net margin of 40.44% and a return on equity of 19.33%. The company's quarterly revenue was up 17.2% on a year-over-year basis. During the same period in the previous year, the company posted $6.17 EPS. On average, analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently commented on the stock. HC Wainwright reissued a "buy" rating and issued a $425.00 price objective on shares of United Therapeutics in a research note on Monday, May 5th. Cantor Fitzgerald assumed coverage on shares of United Therapeutics in a research note on Monday, June 2nd. They issued an "overweight" rating and a $405.00 price objective for the company. JPMorgan Chase & Co. decreased their price target on shares of United Therapeutics from $350.00 to $330.00 and set an "overweight" rating for the company in a research note on Tuesday, July 8th. Wall Street Zen downgraded shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Friday, May 2nd. Finally, UBS Group decreased their price target on shares of United Therapeutics from $410.00 to $385.00 and set a "buy" rating for the company in a research note on Monday, June 30th. Four investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $383.08.

Insider Buying and Selling at United Therapeutics

In other news, Director Richard Giltner sold 3,036 shares of United Therapeutics stock in a transaction on Tuesday, June 24th. The shares were sold at an average price of $289.60, for a total value of $879,225.60. Following the transaction, the director directly owned 19,384 shares of the company's stock, valued at $5,613,606.40. The trade was a 13.54% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO James Edgemond sold 12,000 shares of United Therapeutics stock in a transaction on Monday, June 9th. The shares were sold at an average price of $325.37, for a total transaction of $3,904,440.00. Following the completion of the transaction, the chief financial officer directly owned 8,118 shares in the company, valued at $2,641,353.66. The trade was a 59.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 81,681 shares of company stock valued at $24,628,589. Insiders own 10.30% of the company's stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.